Key Points
- CEO Michael Davidson sold 443,707 shares at an average price of $33.25 for a total of $14,753,257.75, cutting his stake by 71.81% to 174,144 shares; the transaction was disclosed in an SEC filing.
- NewAmsterdam reported a sharp earnings miss—EPS of ($0.63) vs. ($0.40) expected and revenue of $0.03M vs. $0.92M expected—resulting in a deeply negative net margin and negative earnings metrics.
- Shares fell about 7.4% (opened $32.83) after the news; analysts hold a consensus rating of "Moderate Buy" with a target price of $47.10, despite mixed upgrades and downgrades.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 443,707 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer directly owned 174,144 shares of the company's stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
NewAmsterdam Pharma Stock Down 7.4%
Shares of NASDAQ NAMS opened at $32.83 on Tuesday. The firm's fifty day moving average is $33.99 and its 200 day moving average is $33.11. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The company has a market cap of $3.77 billion, a price-to-earnings ratio of -18.98 and a beta of 0.04.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). The firm had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on NAMS. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Wednesday, January 21st. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Leerink Partners reiterated an "outperform" rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Wall Street Zen lowered NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, February 21st. Finally, Guggenheim lifted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and a consensus target price of $47.10.
View Our Latest Stock Analysis on NewAmsterdam Pharma
Institutional Investors Weigh In On NewAmsterdam Pharma
A number of institutional investors have recently modified their holdings of NAMS. Seven Fleet Capital Management LP purchased a new stake in NewAmsterdam Pharma during the 4th quarter valued at about $140,000. Empowered Funds LLC purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $85,000. XTX Topco Ltd grew its holdings in shares of NewAmsterdam Pharma by 1,714.1% during the fourth quarter. XTX Topco Ltd now owns 137,492 shares of the company's stock valued at $4,823,000 after buying an additional 129,913 shares during the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of NewAmsterdam Pharma by 32.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company's stock worth $251,000 after purchasing an additional 1,731 shares in the last quarter. Finally, Twinbeech Capital LP purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $961,000. 89.89% of the stock is owned by hedge funds and other institutional investors.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
